Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Patent issued for methods using the NMP66 protein in detection of breast cancer
September 29th, 2005
Matritech (MZT) announced that the U.S. Patent and Trademark Office has issued the company U.S. Patent No. 6,936,424 covering methods of using the NMP66 protein for the detection of breast cancer. Products covered by claims in this patent will be protected until the year 2020. This most recent patent issuance brings the number of U.S. patents owned or exclusively licensed to Matritech to 21. Matritech's patent portfolio also includes numerous foreign patents issued in Europe, Japan, and Canada. The NMP66 breast cancer program in development is based on Matritech's proprietary nuclear matrix protein (NMP) technology. NMPs comprise the protein...
Source: Women's Health Weekly (2005-09-29)
|
